• Sulfadoxine and Pyrimethamine Tablet 500+25mg, 50*3/Box
  • Sulfadoxine and Pyrimethamine Tablet 500+25mg, 50*3/Box
  • Sulfadoxine and Pyrimethamine Tablet 500+25mg, 50*3/Box
  • Sulfadoxine and Pyrimethamine Tablet 500+25mg, 50*3/Box
  • Sulfadoxine and Pyrimethamine Tablet 500+25mg, 50*3/Box
  • Sulfadoxine and Pyrimethamine Tablet 500+25mg, 50*3/Box

Sulfadoxine and Pyrimethamine Tablet 500+25mg, 50*3/Box

Application: Internal Medicine
Usage Mode: For oral administration
Suitable for: Elderly, Children, Adult
State: Solid
Shape: Tablet
Type: Organic Chemicals
Samples:
US$ 0/Piece 1 Piece(Min.Order)
| Request Sample
Customization:

360° Virtual Tour

Diamond Member Since 2015

Suppliers with verified business licenses

Manufacturer/Factory, Trading Company

Basic Info.

Model NO.
AMC12031-02
Pharmaceutical Technology
Chemical Synthesis
Other Specification
500+25mg, 10*10/Box
Transport Package
50*3/Box
Specification
500+25MG
Trademark
Medipharm, Shinepharm, OEM
Origin
China
HS Code
3004901000
Production Capacity
500000 Boxes/ Month

Product Description

l nephritis, BUN and serum creatinine elevation, toxic nephrosis with oliguria and anuria, and crystalluria.
Drug fever, chills, periarteritis nodosa and LE phenomenon have occurred.
Contra-indications:
Repeated prophylactic (prolonged) use in patients with severe renal or hepatic failure, or blood dyscrasias; documented megaloblastic anemia caused by folate deficiency; use in infants younger than 2 mo of age; prophylactic use in pregnancy at term and during lactation; hypersensitivity to pyrimethamine, sulfonamides, or any other ingredient of sulfadoxine/pyrimethamine.
Warning:
Fatalities associated with the administration of sulfonamides, although rare, have occurred due to severe reactions, including fulminant hepatic necrosis, agranulocytosis, aplastic anemia and other blood dyscrasias. Fansidar (sulfadoxine and pyrimethamine) prophylactic regimen has been reported to cause leukopenia during a treatment of 2 months or longer. This leukopenia is generally mild and reversible.
Precautions:
Oral Sulfadoxine and Pyrimethamine has not been evaluated for the treatment of cerebral malaria or other severe manifestations of complicated malaria, including hyperparasitemia, pulmonary edema or renal failure. Patients with severe malaria are not candidates for oral therapy. In the event of recrudescent P. falciparum infections after treatment with Fansidar (sulfadoxine and pyrimethamine) or failure of chemoprophylaxis with Fansidar (sulfadoxine and pyrimethamine) , patients should be treated with a different blood schizonticide.
Sulfadoxine and Pyrimethamine should be given with caution to patients with impaired renal or hepatic function, to those with possible folate deficiency and to those with severe allergy or bronchial asthma. As with some sulfonamide drugs, in glucose-6-phosphate dehydrogenase-deficient individuals, hemolysis may occur. Urinalysis with microscopic examination and renal function tests should be performed during therapy of those patients who have impaired renal function. Excessive sun exposure should be avoided.
Storage instructions:
Store below 25ºC. Protect from moisture and light. Keep out of reach of children  
Sulfadoxine and Pyrimethamine Tablet 500+25mg, 50*3/Box
Production:
Sulfadoxine and Pyrimethamine Tablet 500+25mg, 50*3/BoxInspection:
Sulfadoxine and Pyrimethamine Tablet 500+25mg, 50*3/BoxLoading:
Sulfadoxine and Pyrimethamine Tablet 500+25mg, 50*3/BoxCertificates:

Sulfadoxine and Pyrimethamine Tablet 500+25mg, 50*3/Box

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now

You Might Also Like

360° Virtual Tour

Diamond Member Since 2015

Suppliers with verified business licenses

Manufacturer/Factory, Trading Company
Management System Certification
ISO 9001, GMP, ISO 13485, FSC
Import & Export Mode
Have Own Export License